Indexed metadata
Proof of concept for the clinical effects of oral rilzabrutinib, the first Bruton tyrosine kinase inhibitor for pemphigus vulgaris: the phase II BELIEVE study*
D.F. Murrell, A. Patsatsi, P. Stavropoulos, S. Baum, T. Zeeli, J.S. Kern, A.‐V. Roussaki‐Schulze, R. Sinclair, I.D. Bassukas, D. Thomas, A. Neale, P. Arora, F. Caux, V.P. Werth, S.G. Gourlay, P. Joly
Evidence graph
No public relationships recorded yet.
Integrity note: This page is a factual metadata record created by deterministic ingestion. It is not a claim that the work moves a mathematical frontier or has been independently verified.